Name | 2-[3-[[(4-tert-butylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid |
---|---|
Synonyms |
CP-533536
UNII-L266R6E31E [3-({[4-(2-Methyl-2-propanyl)benzyl](3-pyridinylsulfonyl)amino}methyl)phenoxy]acetic acid Acetic acid, 2-[3-[[[[4-(1,1-dimethylethyl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]- evatanepag CP533536 |
Description | Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.IC50 value: 0.3 nM (EC50)Target PGE2in vitro: CP-533536 is a potent and selective EP2agonist. CP-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets. |
---|---|
Related Catalog | |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 660.2±65.0 °C at 760 mmHg |
Molecular Formula | C25H28N2O5S |
Molecular Weight | 468.565 |
Flash Point | 353.0±34.3 °C |
Exact Mass | 468.171906 |
PSA | 105.18000 |
LogP | 4.78 |
Vapour Pressure | 0.0±2.1 mmHg at 25°C |
Index of Refraction | 1.600 |
Storage condition | 2-8℃ |
~% 223488-57-1 |
Literature: US2005/65133 A1, ; Page/Page column 45 ; |
Precursor 0 | |
---|---|
DownStream 1 | |